Dillon & Associates Inc Immunity Bio, Inc. Transaction History
Dillon & Associates Inc
- $737 Million
- Q2 2025
A detailed history of Dillon & Associates Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Dillon & Associates Inc holds 25,800 shares of IBRX stock, worth $65,532. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,800Holding current value
$65,532% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
274Shares Held
120MCall Options Held
2.5MPut Options Held
3.14M-
Vanguard Group Inc Valley Forge, PA21.8MShares$55.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$29 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC8.76MShares$22.2 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY7.76MShares$19.7 Million0.36% of portfolio
-
Jane Street Group, LLC New York, NY7.72MShares$19.6 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.02B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...